WindMIL Therapeutics, a Baltimore, MD-based clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, completed a $32.5m Series B financing.
The round was led by Qiming Venture Partners USA, with participation from new investors Medivate Partners and Camden Partners Nexus and existing investors Domain Associates and Foxkiser. In conjunction with the funding, Qiming’s Mark McDade and Anna French, Ph.D. joined WindMIL’s Board of Directors.
The company intends to use the funds for the continued development of MILs™ both in their unmodified and genetically-modified forms.
Co-founded by Ivan Borrello, M.D. and Kim Noonan, Ph.D., and led by Brian Halak, Ph.D., Chief Executive Officer, WindMIL leverages bone marrow derived lymphocytes to develop immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with advantages including inherent tumor-specificity, high cytotoxic potential, and long persistence. The company has created an efficient and rapid process to extract, activate and expand these cells, with the result of this process called MILs™. The lead program is in a Phase 2 study in high-risk multiple myeloma with additional programs in solid tumors using MILs™ advancing to the clinic. WindMIL is also advancing programs to supercharge MILs™ through genetic-modification.